Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp Raises FY 2013 Guidance


Thursday, 25 Jul 2013 07:33am EDT 

Celgene Corp announced that for fiscal 2013, it raises adjusted diluted EPS guidance to a range of $5.80-$5.90 from the previous range of $5.55 to $5.65, an increase of approximately 19% over fiscal 2012 adjusted diluted EPS. GAAP diluted EPS is expected to be in the range of $4.17-$4.31 which includes upfront payment expense for collaborations. The Net Product Sales guidance is raised to a range of $4.2-$4.3 billion, from the previous range of $4.1-$4.2 billion, an increase of approximately 13% over fiscal 2012 REVLIMID Net Product Sales. According to I/B/E/S Estimates, analysts are expecting the Company to report EPS of $4.57 for fiscal 2013. 

Company Quote

86.19
-2.93 -3.29%
24 Jul 2014